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Summary
Most human tumors harbor multiple genetic alterations, including dominant mutant oncogenes. It is often not clear which
of these oncogenes are continuously required and which, when inactivated, may inhibit tumorigenesis. Recently, we
developed a vector that mediates suppression of gene expression through RNA interference. Here, we use a retroviral
version of this vector to specifically and stably inhibit expression of only the oncogenic K-RASV12 allele in human tumor
cells. Loss of expression of K-RASV12 leads to loss of anchorage-independent growth and tumorigenicity. These results
indicate that viral delivery of small interfering RNAs can be used for tumor-specific gene therapy to reverse the oncogenic
phenotype of cancer cells.
Introduction teins in a persistently activated GTP-bound state (McCormick,
1989, 1990). In mouse models of lung cancer, somatic activation
of oncogenic K-ras was necessary for early onset of tumors,Human carcinogenesis is a multistep process, often requiring
between 7 and 10 discrete (epi)genetic events that endow the and its continued production for maintenance of tumor viability
(Chin et al., 1999; Fisher et al., 2001; Jackson et al., 2001;cells with ever-increasing proliferative advantage (Hanahan and
Weinberg, 2000). To develop effective anticancer therapies, it Johnson et al., 2001). A complication in using RAS oncogenes as
targets in anticancer therapy is that at present it is not possible tois essential to know which of these events are still required late
in the process of tumor progression to maintain an oncogenic specifically inhibit only the oncogenic RAS alleles. This may be
essential, since the wild-type K-RAS gene appears to be re-phenotype. Simplified mouse models for cancer, in which fewer
genetic alterations are present, have provided evidence that quired for viability, as evidenced by the embryonic lethal pheno-
type of mice nullizygous for K-ras (Johnson et al., 1997). There-continued activity of certain oncogenes is required for tumor
growth (Hahn and Weinberg, 2002). It is far from clear, however, fore, tools are required to effectively inhibit the activity of
oncogenic K-RAS, but not that of the wild-type K-RAS proteinwhich of the many alterations in human cancers are still required
late in tumor progression. This highlights the need for new tech- in normal tissues. We report here that oncogenic alleles of
nology to assess the contribution of individual cancer-causing K-RAS can be specifically and stably inactivated in human can-
genes to the oncogenic phenotype of late-stage human cancers. cer through use of a viral RNA interference vector, leading to
RAS genes are frequently mutated in human cancers, partic- loss of tumorigenicity.
ularly in pancreatic (85%) and colon carcinoma (40%) (Barbacid,
1987; Bos, 1989). The proteins encoded by the RAS genes Results and Discussion
(K-RAS, H-RAS, and N-RAS) are guanine nucleotide binding
proteins that associate with the inner plasma membrane and We have recently developed a vector (pSUPER) that directs the
synthesis of short interfering RNAs (siRNAs) in mammalian cellstransduce external signals to the interior of the cell. They regu-
late a broad spectrum of cellular activities, including prolifera- (Brummelkamp et al., 2002). Through RNA interference, these
short transcripts can inhibit gene expression to the extent thattion, differentiation, and cell survival (Campbell et al., 1998).
Mutant RAS oncogenes often contain point mutations that alter their function is abrogated (Brummelkamp et al., 2002; Tuschl,
2002). To accomplish more efficient delivery of short interferingonly a single amino acid, which locks the oncogenic RAS pro-
S I G N I F I C A N C E
Oncogenes found in human cancer often differ from their normal counterparts by single base mutations only. The technology to
specifically inactivate only the mutant versions of such oncogenes may be essential for safe and effective anticancer therapy, as
the corresponding wild-type alleles may be required for viability of normal cells. We show here that retroviral delivery of short
interfering RNAs can specifically inhibit the mutant K-RASV12 allele in human pancreatic carcinoma, while leaving the wild-type K-RAS
allele untouched. In spite of the fact that pancreatic carcinoma cells have many genetic alterations, loss of K-RASV12 expression
leads to loss of tumorigenicity, indicating that this oncogene is still required late in tumorigenesis to maintain an oncogenic phenotype.
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Figure 1. A retroviral vector that mediates RNA
interference
A: A schematic drawing of retroviral pRETRO-
SUPER RNA interference vector (pRS). DNA frag-
ments containing the H1-RNA promoter with no
insert or with an insert to target human p53 (as
described in Brummelkamp et al., 2002) were
digested (EcoRI-XhoI) from corresponding
pSUPER constructs and cloned into a self-inacti-
vating pMSCV to generate pRS and pRS-p53,
respectively.
B: Human U2-OS cells that stably express the mu-
rine ecotropic receptor (to allow retroviral entry
into cells) were infected with pRS and pRS-p53
retrovirus and selected for one week with puro-
mycin. Polyclonal populations of puromycin-
resistant cells were immunostained for p53 (in
green) and for actin (in red).
C: Whole cell extracts were made from the same
infected polyclonal populations of U2-OS cells
as in B, separated by SDS-polyacrylamide gel
electrophoresis (PAGE), and immunoblotted to
detect p53 protein.
D: Northern blot analysis with total RNA from the
same infected cell population described in B was
preformed and probed with the sense 19 nucleo-
tide targeting p53 sequence.
RNAs, we tested whether retroviruses that carry the pSUPER cassettes in human cells and direct the synthesis of siRNAs to
cassette can mediate gene silencing. We cloned the entire suppress gene expression.
pSUPER expression cassette from a p53 knockdown vector To study the effects of inhibition of oncogenic RAS expres-
(Brummelkamp et al., 2002) into a self-inactivating pMSCV-puro sion on the tumorigenic phenotype of human cancer cells, we
retroviral vector (pRETRO-SUPER-p53 (pRS-p53), Figure 1A). targeted the expression of the endogenous mutant K-RASV12
Viral stocks were generated from this vector and control pRE- allele with our siRNA vector in the human pancreatic cell line
TRO-SUPER vector and used to infect U2-OS cells that express CAPAN-1 (Figure 2A). We have shown recently that a single
the murine ecotropic receptor to allow infection by ecotropic base mismatch in the 19 nt targeting sequence of siRNAs gener-
virus. After infection, cells were drug-selected and immuno- ated by pSUPER completely abrogates suppression of gene
stained for p53 protein. Figure 1B shows that the vast majority expression (Brummelkamp et al., 2002). To target specifically
of the cells which were infected with the pRS-p53 virus stained the mutant K-RASV12 allele, we cloned a 19 nt targeting sequence
only weakly for p53, whereas all the pRS-control infected cells spanning the region encoding valine 12 of mutant K-RAS into
showed a clear nuclear p53 staining. As expected, the red stain- the pSUPER vector, yielding pSUPER-K-RASV12. Figure 2B
ing of the control actin protein was similar in both polyclonal shows that CAPAN-1 human pancreatic carcinoma cells tran-
populations. Western blot analysis of these cells confirmed clear siently transfected with pSUPER-K-RASV12 had significant sup-
suppression of p53 expression mediated by pRS-p53 virus in- pression of endogenous K-RASV12 expression, whereas control
fection (Figure 1C). Consistent with this, Northern blot analysis cyclin-D1 protein levels were unaffected (Figure 2B). We then
with the sense-19 nt p53 target sequence as a probe detected cloned the pSUPER-K-RASV12 cassette into the pRETRO-
21–22 nt siRNAs generated only by the pRS-p53 construct (Fig-
SUPER retroviral vector. pRS-K-RASV12 virus was then used to
ure 1D).
infect CAPAN-1 cells stably expressing the murine-ecotropic
It was shown recently that RNA viruses are sensitive to RNA
receptor. Parental pRS and pRS-p53 viral stocks were usedinterference (Gitlin et al., 2002; Jacque et al., 2002; Novina et al.,
for control infections. Following drug selection, a Western blot2002). Nevertheless, we were able to obtain high-titer retroviral
analysis with anti-K-RAS specific antibodies revealed that thesupernatants of pRS-p53 (106 /ml) in spite of the fact that the
K-RASV12 expression in the pRS-K-RASV12-infected CAPAN-1full-length retroviral transcript produced by pRS-p53 also con-
cells was markedly suppressed compared to control infectionstains the p53 sequence that is targeted by the virally encoded
(Figure 2C). Growth curves and flow cytometry analyses showedsiRNAs. Apparently, the full-length retroviral transcript does not
that knocking down K-RASV12 had no significant effect on thefall victim to self-inflicted RNA interference. One possible expla-
ability of CAPAN-1 cells to proliferate adherently using standardnation could be that the intramolecular base pairing of the p53
tissue culture conditions (data not shown). Next, we tested thetarget sequence with its complementary sequence within the
specificity of our targeting construct by examining the expres-retroviral transcript precludes siRNA recognition. Alternatively,
sion of wt K-RAS. We used EJ cells, which endogenously ex-rapid packaging of retroviral transcript in a viral coat may render
press two wild-type K-RAS alleles, but harbor oncogenicthe full-length transcript relatively resistant to RNA interference.
H-RASV12. Western blot analysis revealed that comparable levelsWhatever the explanation, these results indicate that retroviral
vectors can be used to mediate efficient integration of pSUPER of wt K-RAS protein were expressed in EJ cells, irrespective of
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Figure 2. Selective suppression of oncogenic
K-RASV12
A: Sequences of the wild-type and V12 mutant
alleles of human K-RAS and the predicted mu-
tant-specific short hairpin transcript encoded by
pSUPER-K-RASV12.
B: The 19 nt sequence spanning the V12 mutation
of K-RASV12 was used to generate a pSUPER-K-
RASV12 (pS-K-RASV12) construct, as described
(Brummelkamp et al., 2002). This construct, an
empty pSUPER (pS), and H2B-GFP plasmids were
electroporated into CAPAN-1 cells and whole
cell extracts were prepared as described
(Agami and Bernards, 2000). Immunoblot analy-
sis was preformed using a specific anti-K-RAS an-
tibody and anti-cyclin-D1 as control.
C: The pSUPER cassette, containing the K-RASV12
targeting sequence, was cloned into pRS as de-
scribed in Figure 1, and virus stock was produced.
A stable polyclonal pool of CAPAN-1 cells that
expresses the murine ecotropic receptor was in-
fected with the indicated viral stocks. Cells were
selected with puromycin for three days and
whole cell extracts were used for immunoblot
analysis to detect K-RAS protein and the controls
p53 and actin.
D: Stable polyclonal pools of CAPAN-1 and EJ
cells that express the ecotropic receptor were
infected with the indicated virus stocks, drug se-
lected, and immunoblotted to detect K-RAS,
p53, and actin proteins.
whether they were infected with the same pRS-K-RASV12, pRS- ruling out the possibilities that the EJ cells were not infected or
lacked components necessary for RNA interference (lanes 2p53, or pRS retroviral stocks used for the CAPAN-1 cells (Figure
2D, lanes 1, 3, 4, and 6). In contrast, p53 expression was sup- and 5). Thus, the RNA interference response provoked by the
pRS-K-RASV12 retrovirus is powerful and sufficiently selectivepressed equally by pRS-p53 in both EJ and CAPAN-1 cell types,
Figure 3. Stable and selective loss of tumorigenicity by a retroviral vector that targets the K-RASV12 oncogene
The same CAPAN-1 (harbor mutant K-RASV12) and EJ (harbor wild-type K-RAS) cell populations as in Figure 2 were infected with the indicated RETRO-SUPER
viruses and selected for three days using 3 g/ml puromycin.
A: 2  104 selected cells from the indicated infections were plated in duplicates in 2.5 cm diameter plates containing soft agar. Shown is one representative
of three independent experiments.
B: 1  106 selected cells from pRS and pRS-K-RASV12 infections were injected subcutaneously into athymic nude mice as indicated. Five weeks later, mice
were inspected for the presence of tumors at the site of injection.
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et al., 2002). However, the success of such approaches stillTable 1. Oncogenic properties of cells with knockdown of K-RASV12
awaits the development of an efficient delivery system that canA: Growth in soft agar. The average number of soft agar colonies
affect most of the tumor cells. In addition, these vectors canfrom three independent experiments is represented.
be used to efficiently identify the genetic events that are required
Cell line pRS pRS-K-RASV12 pRS-p53
for cancer cells to manifest a tumorigenic phenotype. Through
CAPAN-1 150–200 0–2 150–200 use of this technology, out of the many genetic alterations pres-
EJ 300–400 300–400 300–400 ent in most human cancer cells, the most effective targets for
B: Tumorigenicity in athymic nude mice of cells infected with drug development can be rapidly identified.
K-RASV12 or control knockdown vector.
Experimental proceduresCell line pRS pRS-K-RASV12
CAPAN-1 6/6 0/6
Antibodies and plasmid construction
The antibodies used in this study were: Human p53 (Do-1) and FL393, cyclin
D1 (M20), K-RAS (F234), and Actin (C-11) from Santa Cruz.
pSUPER and pSUPER-p53 constructs were described previously
(Brummelkamp et al., 2002). To generate the pSUPER-K-RASV12, theto distinguish between the wild-type and K-RASV12 alleles, which
pSUPER vector was digested with BglII and HindIII and the annealed oligosdiffer by one base pair only.
(5gatccccGTTGGAGCTGTTGGCGTAGttcaagagaCTACGCCAACAGCTThe presence of oncogenic K-RAS alleles is frequent in CCAACtttttggaaa3 and 5agcttttccaaaaaGTTGGAGCTGTTGGCGTAGtctc
human tumors, but almost invariably associated with multiple ttgaaCTACGCCAACAGCTCCAACggg3 were ligated into the vector. The 19
other genetic events. To address the question of whether the nt K-RASV12 target sequences are indicated in capitals in the oligonucleotide
sequence; the G-T mutation that generates the Gly-Val substitution in theoncogenic phenotype of late stage human tumors still depends
twelfth amino acid of K-RAS is underlined).on the expression of oncogenic mutant K-RAS, we again used
To generate pRETRO-SUPER (pRS) constructs, a self-inactivating mu-CAPAN-1 cells. One phenotype that is associated with tumori-
rine stem cell virus (pMSCV) plasmid was used. The 3 LTR of the pMSCV
genicity is the ability to grow independent of anchorage when was inactivated by an internal (NheI-XbaI) deletion to generate a self-inacti-
plated in a semisolid media (soft agar assay). We infected vating virus (LTR). Upon integration to the genome of the virus produced
CAPAN-1 and EJ cells with either pRS-K-RASV12 or with control from this vector, the 3 LTR is duplicated to the 5 LTR to generate a
provirus that lacks all of LTR’s enhancer-promoter activities. EcoRI- andpRS-p53 and pRS virus. After drug selection, 2 104 cells were
XhoI-digested inserts from pSUPER, pSUPER-p53, and pSUPER-K-RASV12plated in soft agar and allowed to grow for three weeks. As
(containing the Polymerase III promoter and the targeting inserts) wereexpected from transformed human tumor cell lines, both
cloned into the same sites in the self-inactivating pMSCV viral construct to
CAPAN-1 and EJ cell lines were able to grow and form colonies generate the corresponding pRS constructs.
when infected with pRS and pRS-p53 control viruses (Figure 3A
and Table 1A). In contrast, infection of pRS-K-RASV12 abolished Cell culture, transfection, and retroviral infection
All cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)almost completely the colony growth of CAPAN-1 cells in this
supplemented with 10% fetal calf serum. Ecotropic retroviral supernatantsassay. Importantly, the effect of pRS-K-RASV12 was specific,
were produced by transfection of phoenix packaging cells by calcium-phos-as soft agar growth of EJ cells (which contain the H-RASV12
phate precipitation. 48 hours posttransfection, the tissue culture medium
oncogene) was unaffected (Figure 3A and Table 1A). was filtered through a 0.45 m filter, and the viral supernatant was used for
Finally, we tested if downregulation of K-RASV12 expression infection of cells after addition of 4 g/ml polybrene. Cells were infected for
in CAPAN-1 cells affected their ability to form tumors in nude at least 6 hr and allowed to recover for 24 hr with fresh medium. Infected
cells were selected with puromycin 1–3 g/ml for 48 hr. High efficiencymice. We infected CAPAN-1 cells with either a pRS-K-RASV12
electroporation of cells was performed as described (Agami and Bernards,virus or pRS control virus and drug selected for three days to
2000).eliminate uninfected cells. After this, we injected 1106 infected
Polyclonal pools of U2OS, EJ and CAPAN-1 cells stably carrying the
cells subcutaneously into athymic nude mice. As shown in Fig- murine ecotropic receptor were generated to allow infections with ecotropic
ure 3B and Table 1B, control pRS-infected CAPAN-1 cells gave retroviral supernatants.
rise to tumors within 5 weeks in all mice, whereas none of the
Western blot analysis and immunofluorescencesix animals infected with the pRS-K-RASV12 virus developed
Western blots were carried out using whole cell extracts, separated ontumors.
10%–15% SDS-PAGE gels, and transferred to polyvinylidene difluorideThese results demonstrate that viral vectors can be used
membranes (Millipore). Western blots were developed using enhanced
to integrate expression cassettes in the genomes of human chemiluminescence (Amersham Biosciences, Inc.) following the instructions
cells, which mediate RNA interference to induce persistent loss- of the manufacturer. For immunofluorescence, the cells were fixed in 4%
of-function phenotypes. Vectors like these have at least two paraformaldehyde and stained using antibodies FL-393 against p53 (1:100)
and Phalloidin (1:100) against actin. The second antibody used was fluores-potential applications. In gene therapy, the selective downregu-
cein isothiocyanate-conjugated goat anti-mouse (1:75, DAKO).lation of only the mutant version of a gene allows for highly
specific effects on tumor cells, while leaving the normal cells
Northern blot analysis
untouched. This feature greatly reduces the need to design Cells were infected and selected as described above, and total RNA (30 g)
viral vectors with tumor-specific infection and/or expression. was extracted one week later. RNA was loaded on an 11% denaturing
By designing target sequences that span chromosomal translo- polyacrylamide gel, and separated and blotted as described (Lee et al.,
1993). Membranes were probed with a 32P-labeled sense p53 19 nt probecation breakpoints found in cancer, these vectors may also
corresponding to the target sequence. The control 5S-rRNA band was de-be used to specifically inhibit the chimeric transcripts of these
tected with ethidium bromide staining.translocated chromosomes. The recent demonstration that siR-
NAs can inhibit gene expression in vivo provides further support Soft agar assay
for the notion that oncogene-specific RNA interference may be In DMEM containing 10% serum, 2  104 cells were resuspended in 2 ml
0.4% low melting point agarose (Sigma type VII, catalog no. A-4018) anda viable approach to treat cancer (Lewis et al., 2002; McCaffrey
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Lizak, M.J., Whitsett, J.A., Koretsky, A., and Varmus, H.E. (2001). Inductionseeded, in duplicate, into six-well plates coated with 1% low melting point
and apoptotic regression of lung adenocarcinomas by regulation of a K-Rasagarose in DMEM containing 10% serum. The number of foci was scored
transgene in the presence and absence of tumor suppressor genes. Genesafter 3 weeks.
Dev. 15, 3249–3262.
Tumor growth in mice Gitlin, L., Karelsky, S., and Andino, R. (2002). Short interfering RNA confers
For analysis of the tumorigenic capacity of CAPAN-1 cells in vivo, 1  106 intracellular antiviral immunity in human cells. Nature 418, 430–434.
cells, infected and selected with either pRS or pRS-K-RASV12 as described
Hahn, W.C., and Weinberg, R.A. (2002). Modelling the molecular circuitry ofabove, were injected subcutaneously in each flank of athymic nude mice.
cancer. Nat. Rev. Cancer 2, 331–341.
Tumor growth was scored after 5 weeks.
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